Similar articles

• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Lassen MR, et al. N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016. N Engl J Med. 2008. PMID: 18579812 Clinical Trial.
• Rivaroxaban for thromboprophylaxis.

  ten Cate H, Hamulyak K. ten Cate H, et al. N Engl J Med. 2008 Nov 13;359(20):2174-5; author reply 2176. N Engl J Med. 2008. PMID: 19009676 No abstract available.
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Eriksson BI, et al. N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374. N Engl J Med. 2008. PMID: 18579811 Clinical Trial.
• Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

  Kwong LM. Kwong LM. Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6. Am J Manag Care. 2011. PMID: 21517652 Review.
• Rivaroxaban (Xarelto)--a new oral anticoagulant.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2011 Aug 22;53(1371):65-7. Med Lett Drugs Ther. 2011. PMID: 21860366 Review. No abstract available.